Cell/Gene Therapy Products Take Center Stage In Kick-Off Of CMS “New Technology” Payment Cycle; New Rules On FDA Status Reduce Number Of Candidates For FY25 NTAP “Town Hall”

You must be a logged-in member of this site to view this article.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Alternatively, if your organization already has a license and you do not yet have an account, please click here to request access.